204P Immune-related adverse events (IrAEs) as a predictor of response to immunotherapy in patients with lung cancer

Becerra, Maria Virginia Sánchez; Martínez-Cabañes, Ruth; Gonzalez-Lopez, Andrea; Zhan-Zhou, E.; Sotelo, Victor Manuel Buendia; Esteban, M. C.; Robles, Tamara Pérez; Cámara, Juan Carlos; Cardeña, Ana; Hernando, Susana; Hurtado, Alicia; Moreno, Diana; Olier, C; Rubio, X. Mielgo

doi:10.1016/s1556-0864(21)02046-3

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported a positive association between the incidence of irAEs and the survival outcomes ( 6 , 61 , 62 ), while others have found no such association ( 63 ). A systematic review and meta-analysis has shown that grade ≥3 toxicities were correlated with a better overall response rate, but poor overall survival ( 64 ), while another has linked irAEs with better survival and response ( 7 ).…”

Section: Toxicity Itself As a Biomarkermentioning

confidence: 99%

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences

Gutiérrez

Barahona²

2022

Front. Med.

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have dramatically transformed oncology by prolonging overall survival and yielding better patient tolerance compared to other chemotherapeutic agents. However, numerous questions remain unanswered about the toxicity profile of ICIs, its relationship with the treatment response, and causes underlying the excellent treatment response in some patients, while recalcitrance in others. Research groups have continued to seek biomarkers that may permit the identification of treatment responders and predict toxicity to facilitate cessation of immunotherapy before the development of severe toxicity. However, some studies have found associations between serious adverse events and longer survivorship. The research question entailed determining whether a biomarker is needed to predict severe immune-related adverse events prior to their development or whether providing early treatment for toxicity would inhibit the immune system from attaining a long-lasting anti-tumor effect. Therefore, this review conducted an in-depth analysis into the molecular basis of these observations.

show abstract